A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
about
Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile NeutropeniaAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsNew approaches to sepsis: molecular diagnostics and biomarkers.Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropeniaUse of antifungal drugs in hematologyDiagnostic methods for invasive fungal diseases in patients with hematologic malignanciesDetection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis.Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaLaboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcomeMolecular Diagnostic Testing for Aspergillus.D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.Updated guidelines for managing fungal diseases in hematology patients.Detection and investigation of invasive mould disease.Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies.Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients.A practical critique of antifungal treatment guidelines for haemato-oncologists.A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, AsDiagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Advancing the Field: Evidence for New Management Strategies in Invasive Fungal InfectionsEnhancing molecular approaches for diagnosis of fungal infections.Rapid diagnosis of sepsis.Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.Molecular diagnosis of sepsis: New aspects and recent developments.Diagnostics and susceptibility testing in Aspergillus.Antifungal stewardship considerations for adults and pediatrics.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Evaluating the use of PCR for diagnosing invasive aspergillosis.Clinical considerations in the early treatment of invasive mould infections and disease.Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases.Empirical amphotericin B therapy on day 4 or day 8 of febrile neutropenia.Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of ChinaAnalysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation.
P2860
Q26778187-C2B4949A-E3AE-4BAB-8014-C2E5A4D3C407Q28080147-EBD935DB-682A-46CD-B729-152C8CE91D16Q34303687-8F695D67-C0C8-49A8-A3A3-3D9D4FF4437CQ34430579-E6B9DE1A-7EF5-428A-A3E3-891A2A87834CQ34532546-B56AEFCF-0C06-4800-B799-4645086BE6A1Q35193749-3DF0BAC6-2F93-41D0-BDEB-9CF97207CAF0Q35678982-C400C101-BFF6-4D51-8DF5-05591D16269AQ36364856-D6F34ADE-1258-4FB8-BCCA-C0A819A91BCBQ36584898-8A380DF1-6A8B-43A8-9DB3-277F27C0B5D6Q36620870-D4202E66-9F02-4D30-A6FC-838928098501Q37220711-2CB57DB3-A04F-4ACC-B78A-0B6665EA175FQ37287794-D7BBD0CA-25DB-4CAA-B64C-4B338AC72AE6Q37363385-97FF542E-4519-4374-9CDE-3A3C3D23576EQ37401327-00258BAF-F8C4-484C-8174-61AE8B793CDBQ37469829-305A112B-58D9-4564-B276-3C92CE7B6D42Q37480190-CFEDDD5D-A0AC-4423-9A79-9F9B712E3A16Q37785548-83ACB8FE-DBF0-4FA0-B298-BEB39EF7034EQ37823011-2E4B60E0-D639-46E9-8ABE-7181A5AAF6A0Q37833638-D6AA26D1-7B8C-49DD-BB4C-3066B6F73CACQ37875790-1B4D9DE2-D858-4C08-9373-7C8EC9D2097EQ37918556-E5C901EE-B067-4384-BFC7-804628BD9ED6Q37934487-76727793-F5F0-40D7-8D7C-BD76689D65D3Q37983106-C286EEDF-1D9F-49BD-9510-5C9C287BF774Q38049498-09F4FE1B-DC5D-4356-9F5A-CBBC70AB0012Q38079194-BE0EAEB7-07AE-465A-8E85-CB8A6E696272Q38082740-2DA9BE4D-8810-4C1B-8666-16A6BD6F35EBQ38165198-6EFAD399-842B-44E7-AD65-8B11E683470CQ38171058-BF01044F-57FF-424B-BE37-63FA6D4FDBCAQ38263489-6F5CBDD6-123F-4126-BBE3-2FDBDFDF49E5Q38284458-AC226266-36D6-425A-A127-FE8F0308A136Q38286512-79AC7C98-ABBA-4451-908A-0609282877B5Q38723910-FB836BB3-381A-4CB2-96EC-9FF6D266DC01Q38944746-682515FB-0EB1-4F50-851C-B673F53E8843Q39196802-E33758DE-F26E-46DE-9F25-E690340CBC45Q39275780-47E0D58C-4101-4A84-88CD-93181EE8FBE1Q40063394-8759E0F7-FC19-4243-8A90-5CFD40E1C776Q40174281-18576306-D042-4139-B0D1-AF57E383F742Q40241548-3611706A-FACB-4074-AB8D-460C5C8A3035Q40629298-01135EBE-0622-4F91-8500-C1415D053DDAQ40886644-E9E57663-CE70-4ABC-9481-233A6957919A
P2860
A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A prospective randomized contr ...... B in patients after allo-SCT.
@en
A prospective randomized contr ...... B in patients after allo-SCT.
@nl
type
label
A prospective randomized contr ...... B in patients after allo-SCT.
@en
A prospective randomized contr ...... B in patients after allo-SCT.
@nl
prefLabel
A prospective randomized contr ...... B in patients after allo-SCT.
@en
A prospective randomized contr ...... B in patients after allo-SCT.
@nl
P2093
P2860
P356
P1476
A prospective randomized contr ...... B in patients after allo-SCT.
@en
P2093
H J Dornbusch
J Loeffler
J Tollemar
K Schaefer-Eckart
L Klingspor
P2860
P2888
P304
P356
10.1038/BMT.2008.355
P407
P50
P577
2008-12-15T00:00:00Z